Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Sponsor
Sun Yat-sen University
Study ID
NCT04294511
Phase
PHASE2
Status
Unknown

Conditions

  • Osteosarcoma

Eligibility Criteria

Sex
ALL
Age
14 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Key Dates

Start date
Dec 26, 2019
Status verified
Mar 2020
Primary completion
Mar 16, 2021
Completion
Sep 16, 2023

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate

Primary Outcome Measure

tumor cell necrosis rate (TCNR) [ Time Frame: 24 months ]

Central Contacts

Related Studies